Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

The development of pathogenic antibody inhibitors against coagulation factor VIII (FVIII) occurs in ∼30% of patients with congenital hemophilia A receiving FVIII replacement therapy, as well as in all cases of acquired hemophilia A. KM33 is an anti–C1 domain antibody inhibitor previously isolated fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Childers, Kenneth C., Avery, Nathan G., Estrada Alamo, Kevin A., Davulcu, Omar, Haynes, Rose Marie, Lollar, Pete, Doering, Christopher B., Coxon, Carmen H., Spiegel, P. Clint
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352601/
https://www.ncbi.nlm.nih.gov/pubmed/37192299
http://dx.doi.org/10.1182/blood.2023020181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352601/
https://www.ncbi.nlm.nih.gov/pubmed/37192299
http://dx.doi.org/10.1182/blood.2023020181

Ejemplares similares